Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 9:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1921–1944 of 17,851 matching trials from the live ClinicalTrials.gov search.
Withdrawn Not applicable Interventional Accepts healthy volunteers

Electrical Nerve Stimulation of the Ulnar Nerve

NCT02566616
Conditions
Cubital Tunnel Syndrome
Interventions
Ulnar Nerve Stimulation
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Nasal Cavity Squamous Cell Carcinoma, Metastatic Nasopharyngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Metastatic Sinonasal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Recurrent Pharyngeal Squamous Cell Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage IV Hypopharyngeal Carcinoma AJCC v8, Stage IV Laryngeal Cancer AJCC v8, Stage IV Lip and Oral Cavity Cancer AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8, Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IV Sinonasal Cancer AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Carboplatin, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Echocardiography Test, Magnetic Resonance Imaging, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
172
States / cities
Little Rock, Arkansas • Dublin, California • Emeryville, California + 135 more
Conditions
Hypercholesterolemia
Interventions
pravastatin tablets and Welchol tablets, pravastatin tablets and Welchol placebo tablets
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
15
States / cities
Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 12 more
Conditions
Pouchitis
Interventions
Vedolizumab Placebo, Ciprofloxacin, Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
10
States / cities
Chicago, Illinois • Evanston, Illinois • Minneapolis, Minnesota + 7 more
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Vedolizumab
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
27
States / cities
Los Angeles, California • Orange, California • San Francisco, California + 22 more
Completed Not applicable Interventional Accepts healthy volunteers

Partner Services Pre-exposure Prophylaxis (PS-PrEP)

NCT02749955
Conditions
HIV Transmission, Transtheoretical Model of Change
Interventions
PS-PrEP Intervention Group, PrEPLine Control Group
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Bipolar Disorder
Interventions
lamotrigine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
308
States / cities
Albertville, Alabama • Anniston, Alabama • Birmingham, Alabama + 254 more
Conditions
Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions
Kerendia (Finerenone, BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
4,613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
38
States / cities
Huntsville, Alabama • Phoenix, Arizona • Harrisburg, Arkansas + 33 more
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Interventions
alvocidib, irinotecan hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
5
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 2 more
Conditions
Pancreatic Cancer, Liver Cancer (Locally Advanced or Metastatic), Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage III, Pancreatic Cancer Stage IV, Liver Cancer Stage IV, Liver Cancer Stage IIIa, Liver Cancer Stage IIIb, Liver Cancer Stage IIIc
Interventions
EUS-Guided MWA Device
Device
Lead sponsor
Banner Health
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Gilbert, Arizona • Los Angeles, California • Chicago, Illinois + 3 more
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
19
States / cities
San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more
Conditions
Hemophilia B
Interventions
rFIXFc
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Chicago, Illinois • Indianapolis, Indiana • Boston, Massachusetts + 3 more
Conditions
Proliferative Diabetic Retinopathy (PDR)
Interventions
Vitrectomy, Endolaser, Faricimab, Panretinal Photocoagulation (PRP)
Procedure · Device · Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
34
States / cities
Huntington Beach, California • Loma Linda, California • San Francisco, California + 30 more
Conditions
Preleukemia, Myeloproliferative Disorders, Lymphoma, Myeloma, Graft Versus Host Disease
Interventions
Fludarabine, Melphalan, Campath
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting No phase listed Observational Accepts healthy volunteers

Intalight Reference Database Protocol for VG200D

NCT07751484
Conditions
The Focus of This Study is to Collect OCT Data on Normal Eyes
Interventions
OCT device called VG200D
Device
Lead sponsor
Intalight, Inc
Industry
Eligibility
22 Years and older
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
3
States / cities
San Diego, California • Chicago, Illinois • Bloomington, Indiana
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Mavacamten, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Completed Not applicable Interventional Accepts healthy volunteers

Employing eSBI in HIV Testing for At-risk Youth

NCT02703116
Conditions
HIV, Substance Use
Interventions
Alcohol Use BI, Nutrition Intervention
Behavioral
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
16 Years to 25 Years
Enrollment
464 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Chicago, Illinois
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, PD 0332991
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
16
States / cities
Chicago, Illinois • Kansas City, Kansas • Westwood, Kansas + 9 more
Conditions
Cystic Fibrosis
Interventions
Placebo, QBW251
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more
Conditions
Myelodysplastic Syndromes
Interventions
Luspatercept, Epoetin Alfa
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
33
States / cities
Clovis, California • Fountain Valley, California • Los Alamitos, California + 30 more
Conditions
Keratoconus
Interventions
Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment
Combination Product
Lead sponsor
Epion Therapeutics
Industry
Eligibility
8 Years to 45 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • Tucson, Arizona • Murrieta, California + 9 more
Conditions
High-risk Muscle Invasive Urothelial Carcinoma
Interventions
Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
19
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more
Conditions
Invasive Fungal Disease, Fever and Neutropenia, Invasive Fungal Infections, Immunocompromised
Interventions
Not listed
Lead sponsor
Karius, Inc.
Industry
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Neuroblastoma
Interventions
irinotecan hydrochloride, temozolomide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
110
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 96 more